~~<i id='DB5BF0D5D3'><strike id='DB5BF0D5D3'><tt id='DB5BF0D5D3'><pre id='DB5BF0D5D3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：entertainment 2025-09-02 17:42:39 - browse：82

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Study identifies new proteins linked to dementia risk 25 years later

leisure time

entertainment

focus

leisure time

AdobeThisarticlewasadaptedfromSTAT’slatestreport,“Failedtrial,successfuldrug:howanegativereadoutcans

WSS

Ending racial health disparities hinges on penalties, political will

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

NIH trials fail to test meaningful long Covid therapies, experts say

I learned firsthand about improving diversity in clinical trials

DeSantis talks Trump, trans issues and 'what wokeness is'

knowledge

explore

leisure time

Heart attack and stroke risk calculators need revising

7 more heat

Trump demands the U.S. pay no more for drugs than other countries … again

Driven by the pandemic, applicants flood public health schools

Walensky prepares to leave CDC — and Congress — behind

Stanford president's case begs question: Who takes blame?

Guidelines to prevent youth baseball injuries need more muscle

Awakening the world to the whoosh: A patient's crusade

Activists slam private health insurers over coverage restrictions

Divers poised to search for children washed away in Pennsylvania flash flood

leisure time

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Vir antibody drug aimed at influenza A fails in clinical trial

South Korea throws huge K

Why failed clinical trials don’t always spell doom for a new drug

Ending racial health disparities hinges on penalties, political will

Drastic changes should bring profitability, startup health insurers say

entertainment

focus

leisure time

leisure time